Trial reportCardiovascular therapeutics2014
Melatonin reduces tachycardia in postural tachycardia syndrome: a randomized, crossover trial.
Trial report in Cardiovascular therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS).Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Pooled it
- Effect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome.Journal of the American College of Cardiology · 2021Trial
- Splanchnic Venous Compression Enhances the Effects of ß-Blockade in the Treatment of Postural Tachycardia Syndrome.Journal of the American Heart Association · 2020Trial
- Efficacy of Propranolol, Bisoprolol, and Pyridostigmine for Postural Tachycardia Syndrome: a Randomized Clinical Trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Trial
- Interaction between clock genes, melatonin and cardiovascular outcomes from ICU patients.Intensive care medicine experimental · 2025Article
- Melatonin-induced symptomatic bradycardia in an otherwise healthy male: a case report.Oxford medical case reports · 2024Article
- Objective Hemodynamic Cardiovascular Autonomic Abnormalities in Post-Acute Sequelae of COVID-19.The Canadian journal of cardiology · 2023Article
- Choices and Challenges With Drug Therapy in Postural Orthostatic Tachycardia Syndrome: A Systematic Review.Cureus · 2023Review
- Melatonin as a protective agent in cardiac ischemia-reperfusion injury: Vision/Illusion?European journal of pharmacology · 2020Review
- Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2020Review
- Melatonin Relations with Energy Metabolism as Possibly Involved in Fatal Mountain Road Traffic Accidents.International journal of molecular sciences · 2020Review
- Cardioprotective Melatonin: Translating from Proof-of-Concept Studies to Therapeutic Use.International journal of molecular sciences · 2019Review
- Sleep Disorders and Their Management in Children With Ehlers-Danlos Syndrome Referred to Sleep Clinics.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018Article
- Cardiovascular Benefits of Dietary Melatonin: A Myth or a Reality?Frontiers in physiology · 2018Review
- Objective Sleep Assessments in Patients with Postural Tachycardia Syndrome using Overnight Polysomnograms.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPostural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance with an excessive increase in heart rate (HR) upon standing, and many POTS patients have a hyperadrenergic state. Medications that restrain HR are a promising approach to this problem.
objectiveWe tested the hypothesis that melatonin will attenuate the tachycardia and improve symptom burden in patients with POTS.
methodsPatients with POTS (n = 78) underwent acute drug trials with melatonin 3 mg orally and placebo, on separate mornings, in a randomized crossover design. Blood pressure, HR, and symptoms were assessed while seated and after standing for up to 10 min prior to, and hourly for 4 h following study drug administration.
resultsThe reduction in standing HR was significantly greater 2 h after melatonin compared with placebo (P = 0.017). There was no significant difference in the reduction of systolic blood pressure between melatonin and placebo, either with standing or while seated. The symptom burden was not improved with melatonin compared with placebo.
conclusionOral melatonin produced a modest decrease in standing tachycardia in POTS. Further research is needed to determine the effects of regular night-time use of this medication in POTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.